Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder
NCT04466345 on ClinicalTrials.gov · last registry update 2025-10-02
Finished 27 December 2024, after enrolling 72 people. Primary outcome, as filed: Executive Function Composite Score. semaglutide is approved in the US, but not for psychiatric — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor type
- Other
- Enrollment
- 72
- Started
- 2021-10-06
- Primary completion
- 2024-12-27 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Executive Function Composite Score
Conditions studied
Major Depressive Disorder
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.